2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

31Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.

Cite

CITATION STYLE

APA

Huang, Z., Chavda, V. P., Vora, L. K., Gajjar, N., Apostolopoulos, V., Shah, N., & Chen, Z. S. (2022, April 12). 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.899633

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free